DexTech Medical AB: Phase I/IIa OsteoDex Study Completed, Zero Net Sales
DexTech Medical AB has completed its Phase I/IIa clinical study of OsteoDex for multiple myeloma, reporting no significant adverse events. The company reported zero net sales for the full fiscal year.
DexTech Medical AB announced the completion of its Phase I/IIa clinical study evaluating OsteoDex in patients with multiple myeloma.
All patients in the study have finished their treatment. Those who achieved stable disease continue to be monitored for disease progression. The study met its primary safety endpoint, with no significant OsteoDex-related adverse events reported.
The company reported zero net sales for both the fourth quarter (April-June 2026) and the full fiscal year (July 2025-June 2026). The operating loss for the fourth quarter was SEK -1.9 million, compared to SEK -1.6 million in the prior year period. Earnings per share were SEK -0.10.
DexTech Medical AB will continue to follow the patients in the study and focus on the potential for new disease progression.